{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:54:02Z","timestamp":1778925242753,"version":"3.51.4"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Affinity maturation and terminal differentiation of B cells via the germinal center reaction is a complex multistep process controlled by transcription factors that induce or suppress large dynamic transcriptional programs. This occurs via the recruitment of coactivator or corepressor complexes that epigenetically regulate gene expression by post-translationally modifying histones and\/or remodeling chromatin structure. B-cell\u2013intrinsic developmental programs both regulate and respond to interactions with other cells in the germinal center that provide survival and differentiation signals, such as T-follicular helper cells and follicular dendritic cells. Epigenetic and transcriptional programs that naturally occur during B-cell development are hijacked in B-cell lymphoma by genetic alterations that directly or indirectly change the function of transcription factors and\/or chromatin-modifying genes. These in turn skew differentiation toward the tumor cell of origin and alter interactions between lymphoma B cells and other cells within the microenvironment. Understanding the mechanisms by which genetic alterations perturb epigenetic and transcriptional programs regulating B-cell development and immune interactions may identify opportunities to target these programs using epigenetic-modifying agents. Here, we discuss recently published studies centered on follicular lymphoma and diffuse large B-cell lymphoma within the context of prior knowledge, and we highlight how these insights have informed potential avenues for rational therapeutic interventions.<\/jats:p>","DOI":"10.1182\/hematology.2020006908","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T04:48:39Z","timestamp":1607143719000},"page":"95-100","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Harnessing lymphoma epigenetics to improve therapies (article not eligible for CME credit)"],"prefix":"10.1182","volume":"2020","author":[{"given":"Haopeng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma and"},{"name":"Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020121621274702000_B1","article-title":"Pathognomonic and epistatic genetic alterations in B-cell non-Hodgkin lymphoma","author":"Ma","year":"2019","journal-title":"bioRxiv"},{"issue":"5","key":"2020121621274702000_B2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1292; Nat Med. 2018;24(8):1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2020121621274702000_B3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"2020121621274702000_B4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020121621274702000_B5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imr.12755","article-title":"Germinal center-derived lymphomas: the darkest side of humoral immunity","volume":"288","author":"Mlynarczyk","year":"2019","journal-title":"Immunol Rev"},{"issue":"1","key":"2020121621274702000_B6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/imr.12745","article-title":"Molecular pathogenesis of germinal center-derived B cell lymphomas","volume":"288","author":"Pasqualucci","year":"2019","journal-title":"Immunol Rev"},{"issue":"8","key":"2020121621274702000_B7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","author":"Sermer","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2020121621274702000_B8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response","volume":"37","author":"B\u00e9guelin","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"2020121621274702000_B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41588-018-0338-y","article-title":"EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains","volume":"51","author":"Donaldson-Collier","year":"2019","journal-title":"Nat Genet"},{"issue":"4","key":"2020121621274702000_B10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2020121621274702000_B11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"2020121621274702000_B12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"issue":"497","key":"2020121621274702000_B13","doi-asserted-by":"crossref","first-page":"eeav5599","DOI":"10.1126\/scitranslmed.aav5599","article-title":"Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma","volume":"11","author":"Jain","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"2020121621274702000_B14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","article-title":"TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate","volume":"182","author":"Venturutti","year":"2020","journal-title":"Cell"},{"issue":"24","key":"2020121621274702000_B15","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","article-title":"EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis","volume":"116","author":"Velichutina","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020121621274702000_B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.164.1.1","article-title":"Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers","volume":"164","author":"Raaphorst","year":"2000","journal-title":"J Immunol"},{"issue":"7","key":"2020121621274702000_B17","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/eji.200424985","article-title":"Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction","volume":"34","author":"van Galen","year":"2004","journal-title":"Eur J Immunol"},{"issue":"2","key":"2020121621274702000_B18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccell.2016.07.006","article-title":"EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis","volume":"30","author":"B\u00e9guelin","year":"2016","journal-title":"Cancer Cell"},{"issue":"5","key":"2020121621274702000_B19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"6","key":"2020121621274702000_B20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm.4092","article-title":"An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation","volume":"22","author":"Souroullas","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"2020121621274702000_B21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-017-01029-x","article-title":"EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop","volume":"8","author":"B\u00e9guelin","year":"2017","journal-title":"Nat Commun"},{"issue":"49","key":"2020121621274702000_B22","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2020121621274702000_B23","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621274702000_B24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-128096","article-title":"Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma [abstract]","volume":"134","author":"Morschhauser","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2020121621274702000_B25","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"issue":"7337","key":"2020121621274702000_B26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"19","key":"2020121621274702000_B27","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","article-title":"Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice","volume":"129","author":"Garc\u00eda-Ram\u00edrez","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020121621274702000_B28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020121621274702000_B29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"2020121621274702000_B30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"},{"issue":"10","key":"2020121621274702000_B31","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2020121621274702000_B32","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/2159-8290.CD-18-0657","article-title":"TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis","volume":"8","author":"Dominguez","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"2020121621274702000_B33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma [published correction appears in Cancer Cell. 2014;25(4):545-546]","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"issue":"31","key":"2020121621274702000_B34","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2020121621274702000_B35","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"7","key":"2020121621274702000_B36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ni.3460","article-title":"Regulated selection of germinal-center cells into the memory B cell compartment","volume":"17","author":"Shinnakasu","year":"2016","journal-title":"Nat Immunol"},{"issue":"2","key":"2020121621274702000_B37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical epigenetics: seizing opportunities for translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat Rev Genet"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/95\/1795174\/hem2020006908c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/95\/1795174\/hem2020006908c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T15:00:53Z","timestamp":1669993253000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/95\/474352\/Harnessing-lymphoma-epigenetics-to-improve"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020006908","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}